全文获取类型
收费全文 | 1697866篇 |
免费 | 128088篇 |
国内免费 | 3777篇 |
专业分类
耳鼻咽喉 | 21825篇 |
儿科学 | 55915篇 |
妇产科学 | 46521篇 |
基础医学 | 241697篇 |
口腔科学 | 49030篇 |
临床医学 | 152096篇 |
内科学 | 333320篇 |
皮肤病学 | 38772篇 |
神经病学 | 131588篇 |
特种医学 | 64277篇 |
外国民族医学 | 244篇 |
外科学 | 259083篇 |
综合类 | 39243篇 |
现状与发展 | 4篇 |
一般理论 | 548篇 |
预防医学 | 125072篇 |
眼科学 | 40273篇 |
药学 | 124224篇 |
7篇 | |
中国医学 | 4358篇 |
肿瘤学 | 101634篇 |
出版年
2019年 | 13825篇 |
2018年 | 20291篇 |
2017年 | 15485篇 |
2016年 | 16868篇 |
2015年 | 19268篇 |
2014年 | 26665篇 |
2013年 | 38580篇 |
2012年 | 53588篇 |
2011年 | 56287篇 |
2010年 | 33234篇 |
2009年 | 31105篇 |
2008年 | 52238篇 |
2007年 | 55545篇 |
2006年 | 55993篇 |
2005年 | 53222篇 |
2004年 | 51377篇 |
2003年 | 48672篇 |
2002年 | 46810篇 |
2001年 | 92021篇 |
2000年 | 93799篇 |
1999年 | 76916篇 |
1998年 | 18927篇 |
1997年 | 16409篇 |
1996年 | 16543篇 |
1995年 | 16766篇 |
1994年 | 15356篇 |
1993年 | 14095篇 |
1992年 | 57596篇 |
1991年 | 55522篇 |
1990年 | 53216篇 |
1989年 | 50980篇 |
1988年 | 46352篇 |
1987年 | 45141篇 |
1986年 | 42433篇 |
1985年 | 40223篇 |
1984年 | 29510篇 |
1983年 | 24991篇 |
1982年 | 13983篇 |
1981年 | 12434篇 |
1979年 | 25625篇 |
1978年 | 17672篇 |
1977年 | 14960篇 |
1976年 | 13945篇 |
1975年 | 14610篇 |
1974年 | 17707篇 |
1973年 | 17032篇 |
1972年 | 15774篇 |
1971年 | 14532篇 |
1970年 | 13499篇 |
1969年 | 12590篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
11.
12.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
13.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
14.
15.
Münch F. Purbojo A. Wenzel F. Kohl M. Dittrich S. Rauh M. Zimmermann R. Kwapil N. 《Der Anaesthesist》2022,71(11):882-892
Die Anaesthesiologie - Die Transfusion von Erythrozytenkonzentraten (EK) ist mit verschiedenen Nebenwirkungen assoziiert, die u. a. durch Lagerungsschäden an Erythrozyten hervorgerufen... 相似文献
16.
17.
18.
19.
Brede H. Eschliman MPH Hongmai H. Pham MD PhD Amol S. Navathe MD PhD Karen M. Dale BSN MSN Julian Harris MD MBA 《Health services research》2023,58(Z3):311-317
Objective
The aim was to identify healthcare payment and financing reforms to promote health equity and ways that the Agency for Healthcare Research and Quality (AHRQ) may promote those reforms.Data Sources and Study Setting
AHRQ convened a payment and financing workgroup–the authors of this paper–as part of its Health Equity Summit held in July 2022. This workgroup drew from its collective experience with healthcare payment and financing reform, as well as feedback from participants in a session at the Health Equity Summit, to identify the evidence base and promising paths for reforms to promote health equity.Study Design
The payment and financing workgroup developed an outline of reforms to promote health equity, presented the outline to participants in the payment and financing session of the July 2022 AHRQ Health Equity Summit, and integrated feedback from the participants.Data Collection/Extraction Methods
This paper did not require novel data collection; the authors collected the data from the existing evidence base.Principal Findings
The paper outlines root causes of health inequity and corresponding potential reforms in five domains: (1) the differential distribution of resources between healthcare providers serving different communities, (2) scarcity of financing for populations most in need, (3) lack of integration/accountability, (4) patient cost barriers to care, and (5) bias in provider behavior and diagnostic tools.Conclusions
Additional research is necessary to determine whether the proposed reforms are effective in promoting health equity. 相似文献20.
Paul G. Richardson Fredrik Schjesvold Katja Weisel Philippe Moreau Larry D. Anderson Darrell White Paula Rodriguez-Otero Pieter Sonneveld Monika Engelhardt Matthew Jenner Alessandro Corso Jan Dürig Michel Pavic Morten Salomo Meral Beksac Albert Oriol Jindriska Lindsay Anna Marina Liberati Monica Galli Pawel Robak Alessandra Larocca Munci Yagci Filiz Vural Abraham S. Kanate Ruiyun Jiang Lara Grote Teresa Peluso Meletios Dimopoulos 《European journal of haematology》2022,108(1):73-83